Company updateOct 14, 2026Medincell Announces New Publication Date for Its Half-Year Financial Result (April 1st – September 30, 2026)Medincell S.A.Medincell issuer announcements · Euronext
Company updateOct 13, 2026Medincell Brings Total Non-Dilutive Financing Secured Since July 2026 to €41.8 Million with an Additional €13.8 Million LoanMedincell S.A.Medincell issuer announcements · Euronext
Company updateOct 9, 2026Medincell Achieves Major Milestone with U.S. FDA Approval of WELTRUZA™ (olanzapine)Medincell S.A.Medincell issuer announcements · Euronext
Company updateOct 9, 2026Medincell Announces the Temporary Suspension of Trading in Its Shares on Euronext ParisMedincell S.A.Medincell issuer announcements · Euronext
Company updateOct 9, 2026Medincell Announces Resumption of Trading in Its Shares on Euronext Paris as of 2:45pmMedincell S.A.Medincell issuer announcements · Euronext
Company updateSep 30, 2026Medincell Extends Remote Voting Deadline for its Annual General Meeting Until 3:00 p.m. TodayMedincell S.A.Medincell issuer announcements · Euronext
Company updateSep 9, 2026Medincell to Participate in Upcoming Investor ConferencesMedincell S.A.Medincell issuer announcements · Euronext